ERBB2 and head and neck squamous cell carcinoma: In short, the expression of TMEM16A can predict the efficacy of EGFR/HER2 inhibitors in BC and HNSCC patients and monitor the recurrence situation, and can be used as a biomarker to predict the efficacy of imatinib in treating GIST patients.